Last updated: August 21, 2026
Zyrtec Allergy is a mature, over-the-counter cetirizine brand owned by Kenvue Inc. Its commercial position is supported by strong consumer recognition, broad retail distribution, and demand for once-daily allergy relief. Its financial profile differs from an innovative prescription drug: patent exclusivity has largely expired, generic and store-brand competition is extensive, and Kenvue does not publicly disclose Zyrtec revenue as a standalone line item.
Kenvue’s Self Care segment, which includes Zyrtec, generated roughly $6 billion in annual sales in recent reporting periods. The brand’s future growth depends on pricing, seasonal allergy severity, formulation extensions, international penetration, digital commerce, and brand investment rather than on patent protection. [1]
What is Zyrtec Allergy and who owns the brand?
Zyrtec Allergy contains cetirizine hydrochloride, a second-generation H1 antihistamine used for temporary relief of sneezing, runny nose, itchy nose or throat, and itchy or watery eyes caused by hay fever or other respiratory allergies. The brand also markets products for indoor and outdoor allergies and, in some markets, formulations directed at allergy-related skin symptoms.
Kenvue owns and commercializes the brand following the separation of Johnson & Johnson’s consumer-health business in 2023. Before the separation, Johnson & Johnson obtained Zyrtec through its 2006 acquisition of Pfizer Consumer Healthcare. [2]
| Item |
Status |
| Active ingredient |
Cetirizine hydrochloride |
| Primary therapeutic category |
OTC systemic antihistamine |
| Original prescription approval |
FDA approval in the 1990s |
| U.S. OTC switch |
2007 |
| Current brand owner |
Kenvue Inc. |
| Original commercial predecessor |
UCB |
| Principal competitors |
Claritin, Allegra, Xyzal, Benadryl, store brands |
| U.S. prescription status |
Generic cetirizine products remain available |
| U.S. branded status |
Over the counter |
Zyrtec is sold in tablets, chewable tablets, liquid gels, syrup or oral-solution formats, and combination products in selected markets. Product availability varies by country.
How has Zyrtec’s financial trajectory developed?
Zyrtec’s brand-level revenue is not separately reported by Kenvue. Investors therefore must use Kenvue’s Self Care segment, retail scanner data, market-share reports, and company commentary to assess performance.
Kenvue reported consolidated sales of approximately $15 billion in recent fiscal years. Self Care, which includes allergy, cough, cold, pain, digestive health, and other consumer products, contributes approximately $6 billion annually. Zyrtec is one of the segment’s major allergy brands, but the company does not disclose its individual revenue, operating margin, advertising spend, or regional profitability. [1]
Kenvue financial indicators
| Metric |
Commercial implication |
| Kenvue consolidated sales |
Indicates the scale of the parent company, not Zyrtec-specific revenue |
| Self Care sales |
Includes Zyrtec and several non-allergy brands |
| Zyrtec standalone sales |
Not publicly disclosed |
| Gross-margin profile |
Typically supported by mature OTC pricing and established manufacturing |
| R&D intensity |
Lower than for prescription medicines because the active ingredient is generic |
| Marketing intensity |
Material because consumer recognition and shelf placement drive share |
| Main earnings risks |
Retailer bargaining, private-label substitution, input costs, seasonality, and advertising efficiency |
Zyrtec’s financial trajectory has likely followed the pattern of a mature branded OTC medicine:
- Prescription-to-OTC expansion: The 2007 switch expanded consumer access and increased retail distribution.
- Post-switch brand scaling: Zyrtec benefited from national advertising, retailer placement, and consumer awareness.
- Generic and private-label erosion: Cetirizine became widely available at lower prices after the loss of prescription exclusivity.
- Brand-price segmentation: The branded product preserves a premium over store brands through trust, convenience, packaging, and marketing.
- Portfolio-based growth: Kenvue can increase revenue through product variants and distribution rather than new chemical-entity innovation.
The brand’s revenue is also seasonal. Sales generally rise during spring and early summer pollen periods, although indoor allergens, climate variation, and year-round allergic rhinitis reduce dependence on a single season. Severe pollen seasons and longer growing seasons can increase category demand, while mild seasons and consumer trade-down can reduce branded sales.
What patents protect Zyrtec Allergy?
No meaningful U.S. patent exclusivity protects the core cetirizine business today. Cetirizine has been available as a generic active ingredient for many years, and the original compound and prescription-product exclusivities expired before the product became a mass-market OTC brand.
The relevant commercial protection now comes from trademarks, packaging, formulation know-how, regulatory compliance, advertising claims, distribution, and consumer loyalty.
| IP category |
Current importance for Zyrtec |
| Core compound patent |
Expired |
| Prescription product patent |
Expired or commercially irrelevant |
| OTC formulation patents |
Limited strategic effect; competitors can market equivalent cetirizine products |
| Method-of-use patents |
No material barrier to standard allergy indications |
| Trademark rights |
Important for brand recognition and shelf differentiation |
| Trade dress and packaging |
Important but narrower than patent exclusivity |
| Manufacturing know-how |
Relevant to quality, cost, and supply continuity |
| Regulatory exclusivity |
No current exclusivity comparable to a new prescription drug |
The brand can pursue patents on delivery systems, packaging, combination products, or specific formulations. Those rights would not recreate broad exclusivity over cetirizine itself. A formulation patent must cover a commercially meaningful technical difference and withstand invalidity and non-infringement challenges.
When does Zyrtec lose exclusivity?
Zyrtec has already lost effective market exclusivity for cetirizine. The product’s major commercial transition occurred when cetirizine moved from prescription to OTC status in 2007. Generic prescription cetirizine products were already competing by that period, and OTC private-label products later expanded the price pressure.
Exclusivity timeline
| Date or period |
Event |
| 1990s |
FDA approval of cetirizine prescription products |
| 2000s |
Generic cetirizine competition develops |
| 2006 |
Johnson & Johnson acquires Pfizer Consumer Healthcare, including Zyrtec |
| 2007 |
FDA permits OTC marketing of Zyrtec |
| 2007 onward |
Branded OTC and store-brand cetirizine compete nationally |
| 2023 |
Kenvue becomes the owner of the consumer-health portfolio |
| Current |
No broad patent or regulatory exclusivity protects cetirizine |
Zyrtec’s commercial defense is therefore a brand strategy, not an exclusivity strategy. The key questions are share retention, price elasticity, product placement, and the return on consumer advertising.
What is the FDA regulatory and Orange Book status of Zyrtec?
Zyrtec is an FDA-regulated OTC drug. The principal U.S. regulatory framework is the FDA OTC monograph system for antihistamine products rather than the market exclusivity structure used for a newly approved prescription product.
The FDA’s OTC Monograph Order Regulation process establishes conditions under which certain nonprescription drugs are generally recognized as safe and effective. Cetirizine products marketed under the applicable regulatory conditions do not require a new, brand-specific approval for every private-label competitor. [3]
Orange Book status
The Orange Book is primarily a listing of approved prescription drug products and their therapeutic equivalence information. It is not the principal source of market protection for ordinary OTC monograph cetirizine products.
| Regulatory issue |
Zyrtec position |
| FDA category |
OTC antihistamine |
| OTC monograph relevance |
High |
| Current new-drug exclusivity |
None of commercial significance |
| Orange Book patent barrier |
No meaningful barrier to ordinary cetirizine competition |
| Generic substitution |
Broadly available for cetirizine products |
| Prescription-to-OTC status |
Product class has been available OTC since 2007 |
Which companies compete with Zyrtec Allergy?
Zyrtec competes in a crowded nonprescription allergy market. The most direct branded rivals are Claritin, Allegra, and Xyzal. Store-brand cetirizine is the closest substitute because it contains the same active ingredient.
| Brand |
Active ingredient |
Company or owner |
Competitive position |
| Zyrtec Allergy |
Cetirizine |
Kenvue |
Strong brand recognition and broad distribution |
| Claritin |
Loratadine |
Bayer |
Once-daily, non-drowsy allergy positioning |
| Allegra Allergy |
Fexofenadine |
Opella/Sanofi consumer-health portfolio |
Non-drowsy positioning and broad product range |
| Xyzal Allergy 24HR |
Levocetirizine |
Haleon |
Later-generation cetirizine-related positioning |
| Benadryl |
Diphenhydramine |
Kenvue |
Older antihistamine with stronger sedation profile |
| Store-brand cetirizine |
Cetirizine |
Retailers and private-label manufacturers |
Primary price competitor |
Zyrtec has a direct ingredient advantage over brands that use different antihistamines only when consumers prefer cetirizine’s perceived effectiveness or duration. That advantage is not protected by patent law. Retailers can replace branded Zyrtec with private-label cetirizine when price gaps become too wide.
How does Zyrtec compare with Claritin and Allegra?
Zyrtec, Claritin, and Allegra compete on similar consumer claims: 24-hour relief, non-drowsiness, and treatment of common allergy symptoms. The clinical and commercial differences are narrower than the brand positioning suggests.
| Factor |
Zyrtec |
Claritin |
Allegra |
| Active ingredient |
Cetirizine |
Loratadine |
Fexofenadine |
| Dosing |
Generally once daily |
Generally once daily |
Generally once daily |
| Price pressure |
High from store-brand cetirizine |
High from store-brand loratadine |
High from store-brand fexofenadine |
| Consumer differentiation |
Strong allergy-brand recognition |
Long-standing non-drowsy positioning |
Non-drowsy and broad seasonal-allergy positioning |
| Patent moat |
None for core ingredient |
None for core ingredient |
None for core ingredient |
| Main strategic lever |
Brand, variants, distribution |
Brand, variants, distribution |
Brand, variants, distribution |
Zyrtec may have a perception of faster or stronger relief for some consumers, while Claritin and Allegra emphasize non-drowsiness and tolerability. These differences support marketing but do not create durable legal exclusivity.
What formulation patents and method-of-use rights protect Zyrtec?
Formulation and delivery patents are secondary assets for Zyrtec. Potentially protected areas include liquid dosage forms, chewable dosage forms, orally disintegrating formats, combination products, packaging that improves dosing or stability, and manufacturing processes.
The commercial value of these rights is limited for three reasons:
- Consumers can purchase ordinary cetirizine tablets from numerous suppliers.
- Competing companies can design around a narrow formulation claim.
- Retailers can sell a standard tablet at substantially lower cost.
Method-of-use patents also have limited value because common allergy indications are established uses of cetirizine. A narrow method claim would need to provide a differentiated clinical or dosing benefit to justify litigation or licensing expenditure.
Are companies challenging Zyrtec through Paragraph IV filings?
There is no material current Paragraph IV challenge directed at the commercial core of Zyrtec. Paragraph IV litigation is generally relevant to an abbreviated new drug application that challenges patents listed for a prescription drug. Zyrtec’s principal U.S. business is an OTC product with an expired core exclusivity position and extensive generic competition.
Past generic entry into prescription cetirizine reduced the legal value of any original prescription patents. Current competitive threats arise through:
- OTC private-label cetirizine;
- generic prescription cetirizine;
- competing branded antihistamines;
- retailer price promotions;
- online substitution and search-based comparison shopping.
A future litigation dispute could involve trademarks, false advertising, packaging, product quality, or a narrow formulation patent. Such a dispute would not ordinarily block the broader cetirizine market.
What litigation and settlement agreements affect Zyrtec?
No major current patent litigation or settlement agreement appears to control the U.S. commercial outlook for standard Zyrtec Allergy products. The relevant historical legal transition was the regulatory and commercial movement from prescription distribution to OTC distribution, followed by generic competition.
The principal legal risks are now conventional consumer-health risks:
- advertising claims that exceed FDA-permitted labeling;
- trademark infringement;
- package or label confusion;
- product-liability claims;
- manufacturing deviations and recalls;
- retailer or distributor contract disputes;
- supply-chain quality issues.
These risks can affect brand equity and costs but do not establish a durable barrier against cetirizine competitors.
What generic launch risks exist for Zyrtec?
Generic launch risk is already realized rather than prospective. The principal threat is continued share migration from branded Zyrtec to lower-priced cetirizine.
Generic and private-label risk drivers
Price gap. A large branded premium encourages consumers and retailers to switch to generic cetirizine.
Retailer control. Pharmacies, mass merchants, warehouse clubs, and online platforms can prioritize private-label inventory.
Low switching costs. Consumers can change antihistamines with limited financial friction.
Ingredient familiarity. The active ingredient is prominently displayed, making substitution easier.
Advertising efficiency. Kenvue must spend to preserve awareness in a category where competitors can benefit from the same clinical ingredient without comparable marketing costs.
Channel mix. E-commerce makes price comparison more transparent and can weaken the value of physical shelf placement.
Zyrtec can resist erosion through premium packaging, multipacks, liquid and chewable formats, physician and pharmacist familiarity, and strong seasonal advertising. These measures protect share but usually cannot prevent category-wide price compression.
How strong is the Zyrtec patent estate?
The patent estate is weak as a barrier to standard cetirizine competition and moderate as a brand-protection platform.
| Dimension |
Assessment |
| Core active ingredient |
Weak; expired |
| Standard tablet protection |
Weak |
| Regulatory exclusivity |
Weak or absent |
| Trademark |
Stronger, subject to enforcement and continued use |
| Consumer awareness |
Strong |
| Retail distribution |
Strong but contestable |
| Manufacturing scale |
Moderate to strong |
| Formulation extensions |
Potentially useful but narrow |
| Litigation leverage |
Limited against ordinary generic cetirizine |
| Licensing value |
Primarily brand, distribution, or product-extension value |
The asset is commercially durable because it is familiar, not because it is legally exclusive.
What licensing deals and ownership changes affect Zyrtec?
The most important ownership transaction was Johnson & Johnson’s acquisition of Pfizer Consumer Healthcare in 2006, followed by the transfer of the consumer-health portfolio to Kenvue in 2023. These transactions changed corporate ownership and capital allocation but did not restore patent exclusivity to cetirizine.
Kenvue’s strategic control includes brand marketing, product development, supply agreements, regulatory management, and retail relationships. Public filings do not identify a Zyrtec-specific licensing arrangement that materially changes its competitive position. [1, 2]
What revenue exposure does Kenvue have to Zyrtec?
Kenvue has meaningful exposure to allergy demand but limited disclosed exposure to Zyrtec as a single product. The company’s risk is diversified across Self Care products and geographic markets.
Zyrtec can affect Kenvue through:
- seasonal allergy sales;
- U.S. mass retail and pharmacy distribution;
- international antihistamine demand;
- brand advertising returns;
- product-extension sales;
- pricing and promotional decisions.
Because Kenvue does not report Zyrtec separately, investors cannot calculate its exact percentage of consolidated revenue or Self Care operating profit from public financial statements. The appropriate valuation approach is to assess Zyrtec as part of the broader Self Care portfolio rather than as an independently reported pharmaceutical asset.
What generic launch scenarios could affect Zyrtec’s market?
The main scenarios are commercial rather than legal.
| Scenario |
Likely effect |
| Stable allergy seasons and controlled promotions |
Broad category stability; Zyrtec retains a premium position |
| Severe pollen seasons |
Higher total category demand and stronger branded sell-through |
| Aggressive retailer private-label pricing |
Faster branded share loss and lower net pricing |
| Increased online substitution |
Greater transparency and higher price elasticity |
| New dosage-form innovation |
Potential stabilization of premium pricing |
| Supply disruption |
Temporary loss of shelf space and consumer switching |
| Strong competitor advertising |
Higher customer-acquisition costs for Kenvue |
| International expansion |
Volume growth with local pricing and regulatory complexity |
What geographic markets does Zyrtec cover?
Zyrtec is commercialized internationally under the Zyrtec name or local equivalents, subject to country-specific regulatory classifications, labeling, and marketing rights. In some jurisdictions, cetirizine is sold as a prescription medicine, while in others it is available over the counter.
Geographic value is highest where:
- seasonal and perennial allergic rhinitis are prevalent;
- OTC pharmacy distribution is developed;
- consumers recognize branded antihistamines;
- Kenvue has established regulatory and retail infrastructure.
International revenue is exposed to foreign-exchange movements, local generic pricing, country-specific reimbursement rules, and differing OTC advertising restrictions.
What manufacturing and intellectual-property barriers protect Zyrtec?
Manufacturing is a moderate operational barrier but a weak market-exclusion barrier. Kenvue benefits from established suppliers, quality systems, scale purchasing, regulatory compliance, and distribution capabilities. Competitors can obtain cetirizine active pharmaceutical ingredient from qualified manufacturers and produce standard dosage forms under applicable regulatory requirements.
The main manufacturing risks are:
- active-ingredient supply concentration;
- packaging-material shortages;
- quality-control failures;
- plant interruptions;
- regulatory inspections;
- retailer service-level requirements.
These issues can affect availability and cost. They do not prevent qualified competitors from entering the market.
Key Takeaways
- Zyrtec Allergy is a mature OTC cetirizine brand owned by Kenvue.
- The core cetirizine patent and prescription exclusivity have expired.
- The brand has no meaningful current patent moat against generic or private-label cetirizine.
- FDA OTC regulation, not new-drug exclusivity, governs the core U.S. business.
- Kenvue does not disclose Zyrtec revenue separately.
- Zyrtec contributes to Kenvue’s Self Care portfolio, which generates roughly $6 billion in annual sales.
- The principal competitors are Claritin, Allegra, Xyzal, and store-brand cetirizine.
- Financial performance depends on brand premium, retail execution, advertising, seasonal allergy demand, and product extensions.
- Paragraph IV litigation is not the main current risk.
- Generic substitution, retailer private labels, and online price comparison are the principal commercial threats.
- Zyrtec’s strongest assets are its trademark, consumer recognition, distribution, and manufacturing platform.
FAQs About Zyrtec Allergy Market and Exclusivity
Is Zyrtec still protected by a patent?
No broad, commercially meaningful patent protects standard cetirizine products. Current protection rests mainly on trademarks, packaging, marketing, and distribution.
Is Zyrtec a prescription drug or an OTC medicine?
Zyrtec is primarily an OTC allergy medicine in the United States. Cetirizine is also available in generic prescription products.
Does Kenvue disclose Zyrtec sales?
No. Kenvue reports broader business segments, including Self Care, but does not publicly provide standalone Zyrtec revenue or profit figures.
Can pharmacies substitute generic cetirizine for Zyrtec?
Yes. Generic cetirizine is widely available, and consumers can select lower-priced products containing the same active ingredient, subject to applicable pharmacy and retail practices.
Is Zyrtec more commercially valuable than Claritin or Allegra?
Public filings do not provide sufficient standalone brand revenue data to establish a definitive ranking. Zyrtec, Claritin, and Allegra are major competing brands, and their relative performance varies by market, season, price, formulation, and advertising.
References
-
Kenvue Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Johnson & Johnson. (2006). Johnson & Johnson completes acquisition of Pfizer Consumer Healthcare. Johnson & Johnson corporate announcement.
-
U.S. Food and Drug Administration. (2024). OTC Monograph Order Regulation and nonprescription drug products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2007). FDA approves over-the-counter Zyrtec for allergy relief. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
